Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicentre Clinical Trial to Assess the Performance of the Xpert MTB/XDR Assay for INH- and Second-line Resistance Detection
Brief Summary: FIND and partners intend to address the need for a multi- and extensively drug-resistant tuberculosis (M/XDR-TB) diagnostic solution for patients in settings with a high burden of drug-resistant tuberculosis (DR-TB) though the development, evaluation and introduction of an Xpert MTB/XDR assay


Options:
A: Arm Label: endTB regimen 1 (BeLiMoZ); Type: EXPERIMENTAL; Interventions: Drug: Bedaquiline, Drug: Moxifloxacin, Drug: Linezolid, Drug: Pyrazinamide | Arm Label: endTB regimen 2 (BeLiCLeZ); Type: EXPERIMENTAL; Interventions: Drug: Bedaquiline, Drug: Clofazimine, Drug: Levofloxacin, Drug: Linezolid, Drug: Pyrazinamide | Arm Label: endTB regimen 3 (BeDeLiLeZ); Type: EXPERIMENTAL; Interventions: Drug: Bedaquiline, Drug: Delamanid, Drug: Levofloxacin, Drug: Linezolid, Drug: Pyrazinamide | Arm Label: endTB regimen 4 (DeLiCLeZ); Type: EXPERIMENTAL; Interventions: Drug: Delamanid, Drug: Clofazimine, Drug: Levofloxacin, Drug: Linezolid, Drug: Pyrazinamide | Arm Label: endTB regimen 5 (DeCMoZ); Type: EXPERIMENTAL; Interventions: Drug: Delamanid, Drug: Clofazimine, Drug: Moxifloxacin, Drug: Pyrazinamide | Arm Label: endTB regimen 6 (Control); Type: ACTIVE_COMPARATOR; Interventions: Drug: Control arm MDR-TB regimen, consistent with WHO guidelines | Intervention Type: DRUG; Name: Bedaquiline; Assigned to Arm(s): endTB regimen 1 (BeLiMoZ), endTB regimen 2 (BeLiCLeZ), endTB regimen 3 (BeDeLiLeZ) | Intervention Type: DRUG; Name: Delamanid; Assigned to Arm(s): endTB regimen 3 (BeDeLiLeZ), endTB regimen 4 (DeLiCLeZ), endTB regimen 5 (DeCMoZ) | Intervention Type: DRUG; Name: Clofazimine; Assigned to Arm(s): endTB regimen 2 (BeLiCLeZ), endTB regimen 4 (DeLiCLeZ), endTB regimen 5 (DeCMoZ) | Intervention Type: DRUG; Name: Levofloxacin; Assigned to Arm(s): endTB regimen 2 (BeLiCLeZ), endTB regimen 3 (BeDeLiLeZ), endTB regimen 4 (DeLiCLeZ) | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): endTB regimen 1 (BeLiMoZ), endTB regimen 5 (DeCMoZ) | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): endTB regimen 1 (BeLiMoZ), endTB regimen 2 (BeLiCLeZ), endTB regimen 3 (BeDeLiLeZ), endTB regimen 4 (DeLiCLeZ) | Intervention Type: DRUG; Name: Pyrazinamide; Assigned to Arm(s): endTB regimen 1 (BeLiMoZ), endTB regimen 2 (BeLiCLeZ), endTB regimen 3 (BeDeLiLeZ), endTB regimen 4 (DeLiCLeZ), endTB regimen 5 (DeCMoZ) | Intervention Type: DRUG; Name: Control arm MDR-TB regimen, consistent with WHO guidelines; Assigned to Arm(s): endTB regimen 6 (Control)
B: Arm Label: Standard Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard treatment | Arm Label: Same-Day Treatment Group; Type: EXPERIMENTAL; Interventions: Other: Same-Day Treatment | Intervention Type: OTHER; Name: Same-Day Treatment; Assigned to Arm(s): Same-Day Treatment Group | Intervention Type: OTHER; Name: Standard treatment; Assigned to Arm(s): Standard Group
C: Arm Label: Bedaquiline + PA-824 + Linezolid; Type: EXPERIMENTAL; Interventions: Drug: Bedaquiline, Drug: PA-824, Drug: Linezolid | Intervention Type: DRUG; Name: Bedaquiline; Assigned to Arm(s): Bedaquiline + PA-824 + Linezolid | Intervention Type: DRUG; Name: PA-824; Assigned to Arm(s): Bedaquiline + PA-824 + Linezolid | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): Bedaquiline + PA-824 + Linezolid
D: Arm Label: TB case detection Group; Type: N/A; Interventions: Device: Cepheid Gene Xpert MTB/XDR | Arm Label: RIF-resistance MTB Group; Type: N/A; Interventions: Device: Cepheid Gene Xpert MTB/XDR | Intervention Type: DEVICE; Name: Cepheid Gene Xpert MTB/XDR; Assigned to Arm(s): RIF-resistance MTB Group, TB case detection Group

Answer: D